Marshall Wace’s Medtronic MDT Stock Holding History

Marshall Wace’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$9.61K	–	3510
2025 Q4	$9.61K	Sell	100 -200	-67%	-$19.4K	﹤0.01%	2859
2025 Q3	$28.6K	Buy	+300	New	+$27.6K	﹤0.01%	2767

Other funds holding MDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's MDT Position: Q1 2026 in Review

Marshall Wace sold out of Medtronic (MDT) in Q1 2026, closing a stake of 79,081 shares — an estimated $7.6M sold.

Marshall Wace first reported a position in MDT in Q1 2014 and held it in 37 quarters. The position peaked at $144M in Q2 2022. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

Marshall Wace reported no remaining Medtronic position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 79,081 Medtronic shares in Q1 2026, an estimated $7.6M.
Marshall Wace first reported a position in Medtronic in Q1 2014 and held it in 37 quarters.
Marshall Wace's Medtronic position peaked at $144M in Q2 2022.
2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.